RenovoRx, Inc. (RNXT)
$1.28-3.76%Close
SELLCRISIS · day 23
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $48M
- Beta
- 0.97
- P/E (TTM)
- -4.39
- Short % float
- 2.38%
- Days to cover
- 1.6
- SI change
- +40.6%
- 1W
- -18.99%
- 1M
- -27.68%
- vs SPY 1W
- -20.15%
- vs SPY 1M
- -30.68%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on RNXT?
- LOPJLB’s latest quantitative signal on RenovoRx, Inc. (RNXT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is RNXT in?
- RenovoRx, Inc. (RNXT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does RenovoRx, Inc. (RNXT) do?
- RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced …